Market capitalization | $97.07m |
Enterprise Value | $49.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.36 |
P/S ratio (TTM) P/S ratio | 2.65 |
P/B ratio (TTM) P/B ratio | 1.79 |
Revenue (TTM) Revenue | $36.69m |
EBIT (operating result TTM) EBIT | $-147.71m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
3 Analysts have issued a Adagio Therapeutics Inc forecast:
3 Analysts have issued a Adagio Therapeutics Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 37 37 |
-
|
|
Gross Profit | 31 31 |
1,608%
1,608%
|
|
EBITDA | -144 -144 |
32%
32%
|
EBIT (Operating Income) EBIT | -148 -148 |
32%
32%
|
Net Profit | -143 -143 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Head office | United States |
CEO | William Duke |
Employees | 99 |
Founded | 2020 |
Website | invivyd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.